




10th Global

DDF Summit

Drug Delivery & Formulation

11 - 13 March 2019 | Berlin

Innovations in pharmaceutical development

Europe's premier drug delivery and formulation event

Summit Brochure



"Great! Very interesting and highly diverse talks"

Benjamin Franzmann
Senior Technician, **Boehringer Ingelheim**

"Confirmation that DDF Summit is a great place for networking and learning what's running in the Drug Delivery space"

Luigi Boltri
R&D Director, **Adare Pharmaceuticals**

"Very good mix – academia, pharma industry and technology providers. High quality presentations with relevant case studies. Good networking opportunity"

Olaf Queckenberg
Head of Chemical and Pharmaceutical Development, **Bayer**

"The DDF Summit is an important event worthy of being attended in the years to come!"

Danilo Aleo
Head of Drug Development, **Medivis**



The perfect mix. The DDF Summit brings together leading formulation development and drug delivery scientists from both industry and academia to share and discuss their latest work.

Quality content. The agenda is packed with carefully selected talks on topics as diverse as the challenges you face.

Invaluable networking. The DDF community is open, friendly and represents an incredibly valuable network of scientists working at the forefront of their field. There is ample networking time built in to help you make and strengthen connections.

Tailor your experience. 4 parallel streams give you the chance to personalise your agenda and delve deep into the topics pertinent to your challenges. Choose from Small Molecules, Biologics, Technology & Innovation or Device Development.

The right size. This year the DDF Summit will be limited to just 500 people, in order to maintain the quality of the networking and comfort for participants. This means that there will only be 250 delegate tickets available. So, don't waste time in getting yours.

Key themes for 2019 include:

- Analytical techniques for biotherapeutics
- mAb and bispecific formulation development
- Oral delivery of biologics and other routes
- Device development and next generation biotherapeutics
- Nanoparticle formulations
- Continuous manufacturing
- Integrating human factors into device development





[Click here for the full agenda](#)

Stream Highlights: Biologics

How Next-Generation Biotherapeutics will Influence Formulation and Device Development

Kerstin Walke

Head of Pharmaceutical Development Biologicals
Boehringer Ingelheim

Analytical Techniques for Biopharmaceutical Evaluation

Marc-Antoine Fabre

Global Head Biopharmacy
Sanofi

Novels Tool for Peptide and Protein Conjugations

Thomas Hoeg-Jensen

Scientific Director
Novo Nordisk

Current Research on GLP-1 with a Special Focus on Semaglutide Oral Delivery

Jesper Lau

Vice President, Protein and Peptide Chemistry
Novo Nordisk

Fill & Finish of Bispecific MaBs

Stephanie Greco

Head of laboratory in Pharmaceutical Engineering
Sanofi

Polysorbate Degradation: Implications and Control

Satya Krishna Kishore Ravuri,

Senior Group Leader, Early-Stage Pharmaceutical and Processing Development
Roche

PS80 Oxidation Case Study: Any Impact on mAb Stability

Heloise Audat

Head of Late Stage Formulation Development Unit, Biologics
Sanofi

Mind the Gap - How to Assure Data Integrity in a High-Throughput Formulation Screening for Biotherapeutics

Sabine Eichling

Senior Scientist II, NBE High Throughput and Advanced Formulation Sciences Drug Product Development
AbbVie

Bispecifics Drug Product Development; Challenge of Low Concentration Analysis and Formulation

Sachin Dubey

Head of Formulation and Analytical Development
Glenmark

Parenteral Sustained Release of Peptides – Getting It Right

Simon Bjerregaard

Senior Research Scientist
Ferring

Visible Particles and Root Causes

Andreas Seidl

Head Global Analytical Characterization & Bioanalytics
Novartis

Challenges and Opportunities for the Next Generation of Oral Peptide Delivery

Alan S Harris

Senior VP, Global R&D Life Cycle Management
Ferring

Characterization of Subvisible Particles: Old Challenges and Newest Improvements

Anacelia Ríos Quiroz

Scientist - Group Leader Particle Lab Biologics
Roche



[Click here for the full agenda](#)

Stream Highlights: Small Molecules

Future Trends in Pharmaceutical Development

Olaf Queckenberg

Head of Chemical & Pharmaceutical Development
Bayer

Nanoparticle Formulation Development: A Closer look at Pharmaceutical Fabrication Methods

Ben Van Hove

Associate Director Drug Product Development, Oral Solid Dosage Forms
Janssen

Advances in Supersaturating Drug Delivery Systems

Prof Rainer Jordan

Professor of Macromolecular Chemistry
TU Dresden

Evaluation of Dry Powder Formulation Approaches for the Improvement of Lung Pharmacokinetics of Poorly Water-Soluble NCEs in Preclinical in-vivo Experiments

Alessandro Fioni

DMPK Senior Scientist
Chiesi

Understanding Material Properties for HME Process Optimization in ASD Formulations

Samuel Kyeremateng

NCE Formulation Sciences Senior Scientist
Abbvie

Application of New Drying Techniques for OSD

Sune Andersen

Principal Scientist Spray Drying
Janssen

Control Strategy Approaches in Continuous Manufacturing of Oral Solid Dosage Forms

Jacqueline Maximilien

Senior Scientist
Janssen

Nanoparticle Based Formulations: Special Emphasis on Bioavailability Improvement and Delayed Release upon Parenteral Administration

Dr. Yogeshwar Bachhav

Associate Director Pharmaceutical Development
AiCuris Anti-infective Cures

Challenges and Opportunities to Include Patient Centred Design in Industrial Drug Development

Dr. Carsten Timpe

Expert Scientist
Roche

3D Printing as an Investigative Tool in Particle Detachment

Tim Rouse

Senior Scientist
Chiesi

Smart Delivery of Actives by Polyrotaxanes Providing New Options for the Treatment of Niemann-Pick Typ C Disease

Gerhard Wenz

Professor
Saarland University



[Click here for the full agenda](#)

Stream Highlights: Technology & Innovation

More Than Just Down-Scaling – Miniaturization of Methods in a High-Throughput Setting Requires Creative Concepts and Holistic Thinking

Dr. Martin Hüelsmeyer

Head of HTS Operations & Analytics NBE Formulation Sciences,
Principal Research Scientist
AbbVie

Penetrating the Blood Brain Barrier (BBB) Using Novel Nanoplatfroms

Johannes Khinast

Director
Research Center Pharmaceutical Engineering

Design, Translation and Development of Polymeric Nano-Medicines

Harivardhan-Reddy Lakkireddy

Head of Drug Delivery Technologies & Innovation - Nanotechnologies
Sanofi

In vitro Models of the Blood Brain Barrier and Their Use in Drug Delivery Studies

Birger Brodin

Faculty of Health and Medical Sciences Department of Pharmacy CNS Drug Delivery and Barrier Modelling
University of Copenhagen

Are We Prepared for the Regulations on Patient-Focused/Patient-Centric Drug Development?

Sven Stegemann

Director, Pharmaceutical Business Development
Lonza

Dr. Carsten Timpe

Expert Scientist
Roche

Release Testing of Nanoformulations

Dr. Matthias G. Wacker

Head of Department, Pharmaceutical Technology and Nanosciences
Fraunhofer-Institute for Molecular Biology and Applied Ecology

Ultra-high Drug Loaded Micellar Drug Formulation and Solid Dispersions

Prof. Dr. Robert Luxenhofer

Chair of Chemical Technology of Materials Synthesis
Wuerzburg University

Early Formulation Tech Innovation

Dr. Elisabeth Kersten

Lab Head Early Formulation Development
Bayer



Keynote



Solution Spotlight



Case Study



Panel

[Click here for
the full agenda](#)

Stream Highlights: Device Development



Drug Delivery Devices for Innovative Parenterals and Biosimilars: Patient-Centered Technical and Business Opportunities

Corinna Sonderegger

Head Portfolio Management Device Development & Commercialization
Novartis



Human Factors Engineering for Medical Device Development

Rémy Vomscheid

Director, Device Development & Technologies
Ipsen



Benefits of Early Integration of Human Factors: A BYDUREON® BCise case study

James Meehan

Associate Principal Scientist – Human Factors
AstraZeneca



MDR Article 117 Impact on Industry

April Kent

Regulatory Affairs Manager, Devices; Device Lead for AMG 162,
IVD Lead for AMG 701 + 596
Amgen



Speakers



Advait Badkar
Senior Director
Pfizer



Alan S Harris
Senior VP, Global R&D Life Cycle
Management
Ferring



Alessandro Fioni
DMPK Senior Scientist
Chiesi



Anacelia Ríos Quiroz
Scientist - Group Leader Particle
Lab Biologics
Roche



Andreas Seidl
Head Global Analytical
Characterization & Bioanalytics
Novartis



Anette Müllertz
Professor, Director of The
Bioneer-FARMA Center
University of Copenhagen



April Kent
Regulatory Affairs Manager,
Devices; Device Lead
Amgen



Beat Steffen
Founder and Chief Executive
Officer
Confinis



Ben Van Hove
Associate Director Drug Product
Development, Oral Solid Dosage
Forms
Janssen



Birger Brodin
Faculty of Health and Medical Sciences
Department of Pharmacy CNS Drug
Delivery and Barrier Modelling
University of Copenhagen



Christer Tannergren
Associate Principal Scientist
in Biopharmaceutics
AstraZeneca



Corinna Sonderegger
Head Portfolio Management
Device Development &
Commercialization
Novartis



Daniel Latham
Head – Device Development
& LCM Device Development &
Commercialisation
Novartis



Dr. Carsten Timpe
Expert Scientist
Roche



Dr. Elisabeth Kersten
Lab Head Early Formulation
Development
Bayer



Gerhard Wenz
Professor
Saarland University



**Harivardhan-Reddy
Lakkireddy**
Head of Drug Delivery Technologies
& Innovation – Nanotechnologies
Sanofi



Heloise Audat
Head of Late Stage Formulation
Development Unit, Biologics
Sanofi



Jacqueline Maximilien
Senior Scientist
Janssen



James Meehan
Associate Principal Scientist –
Human Factors
AstraZeneca



Jesper Lau
Vice President, Protein and
Peptide Chemistry
Novo Nordisk



Johannes Khinast
Scientific Director
**Research Center
Pharmaceutical Engineering
(RCPE)**



Kerstin Walke
Head of Pharmaceutical
Development Biologics
Boehringer Ingelheim



Marc Du Jardin
Associate Director
Janssen



Marc-Antoine Fabre
Global Head Biopharmacy
Sanofi



Mario Maio
Head CMC Development
Polyphor



Mark R.H. Krebs
Head of Formulation
Development
Janssen



Speakers *continued*



Dr. Martin Hüelsmeyer
Head of HTS Operations & Analytics
NBE Formulation Sciences,
Principal Research Scientist
AbbVie



Prof. Rainer Jordan
Professor of Macromolecular
Chemistry
TU Dresden



Satya Krishna Kishore Ravuri
Senior Group Leader, Early-Stage
Pharmaceutical and Processing
Development
Roche



Sven Stegemann
Director, Pharmaceutical
Business Development
Lonza



Dr. Matthias G. Wacker
Head of Department, Pharmaceutical
Technology and Nanosciences
**Fraunhofer-Institute for Molecular
Biology and Applied Ecology**



Rémy Vomscheid
Director, Device Development
& Technologies
Ipsen



Simon Bjerregaard
Senior Research Scientist
Ferring



Thomas Hoeg-Jensen
Scientific Director
Novo Nordisk



Michael Siedler
Head of NBE Formulation
Development - NBE Formulation
Sciences & Process Development
AbbVie



**Prof. Dr. Robert
Luxenhofer**
Chair of Chemical Technology
of Materials Synthesis
Wuerzburg University



Stephanie Greco
Head of laboratory in
Pharmaceutical Engineering
Sanofi



Tim Rouse
Senior Scientist
Chiesi



Mostafa Nakach
Head of Pharmaceutical
Engineering
Sanofi



Sabine Eichling
Senior Scientist II, NBE High
Throughput and Advanced
Formulation Sciences Drug Product
Development
AbbVie



Stephen Buckley
Head of the Discovery ADME
Department in Global Research
Novo Nordisk



Dr. Yogeshwar Bachhav
Associate Director
Pharmaceutical Development
AiCuris Anti-infective Cures



Olaf Queckenberg
Head of Chemical &
Pharmaceutical Development
Bayer



Sachin Dubey
Head of Formulation and
Analytical Development
Glenmark



Steve Bowman
Device Program Lead
Shire



Tina Bjeldskov Pedersen
Head of Department Oral
Formulation Research
Novo Nordisk



Patrick Garidel
Associate Director Protein
Science
Boehringer Ingelheim



Samuel Kyeremateng
NCE Formulation Sciences
Senior Scientist
AbbVie



Sune Andersen
Principal Scientist Spray Drying
Janssen



Commercial Partners

If you're interested in becoming an official partner for the DDF Summit, please contact

Alexandra Krcho

alexandra.krcho@markallengroup.com +44 (0) 203 874 9205.



ADARE
Pharmaceuticals™

Adare Pharmaceuticals
www.adarepharma.com



armorpharma
delivering lactose solutions

Armor Pharma
www.armor-pharma.com



**CAMBRIDGE
DESIGN
PARTNERSHIP**

**Cambridge Design
Partnership**
www.cambridge-design.co.uk



DATWYLER

**Datwyler Pharma
Packaging International**
www.datwyler.com



enable
injections

Enable Injections
www.enableinjections.com



SIO
Quality-Specialty
OILS & FATS

ADM-SIO
www.admsio.com



BACHEM

Bachem
www.bachem.com



CAPTISOL®
A Ligand TECHNOLOGY

**Captisol, a Ligand
technology**
www.ligand.com



DFE pharma

DFE Pharma
www.dfepharma.com



FOSTER
DELIVERY SCIENCE

Foster Delivery Science
www.deliveryscience.com



Albumedix

Albumedix
www.albumedix.com



biopharma
group

Biopharma Group
www.biopharma.co.uk



confinis
regulatory compliance worldwide

Confinis
www.confinis.com



DU PONT®

**DuPont Nutrition &
Health**
www.dupont.com



FREWITT

FREWITT
www.frewitt.com



Commercial Partners *continued*



Halo Labs
www.halolabs.com

Lonza

Pharma & Biotech

Losan Pharma
www.losan-pharma.de



Munit
www.munit.com



PMC Isochem
www.pmcisochem.fr



tesa Labtec GmbH

Tesa Labtec
www.tesa-labtec.com



Hovione
www.hovione.com



LTS Lohmann
www.ltslohm.de



Oakwood Labs
www.oakwoodlabs.com



Quotient Sciences
www.quotientsciences.com



W.L. Gore & Associates
www.gore.com/pharmbio



leon-nanodrugs
www.leon-nanodrugs.com



MedPharm
www.medpharm.com



Pensatech Pharma
www.pensatechpharma.com



Roquette
www.roquette.com



Grace
www.grace.com



Lonza Pharma & Biotech
pharma.lonza.com



Merck KGaA
www.merckgroup.com



Pfanstiehl Inc.
www.pfanstiehl.com



**Shin-Etsu Pharma & Food
Materials Distribution**
www.se-pfmd.com




"The DDF event is getting better with every year... It is really worth coming."

Monika Brink, Senior Manager,
Outsourcing R&D CMC,
Boehringer Ingelheim Vetmedica


Who attends the DDF Summit?

The 2018 summit was the biggest to date with over 420 senior pharmaceutical development leaders joining us in Berlin for the 3 days. Here's how they breakdown:


By job function:



By company type:



By seniority:






Who attends the DDF Summit? *continued*

By country:

Top 10 countries:

1	Germany	24.8%
2	United Kingdom	11.8%
3	United States	9.3%
4	Switzerland	7.8%
5	France	6.8%
6	Belgium	5.8%
7	Denmark	5.3%
8	Italy	4.3%
9	Sweden	3.3%
10	Spain	3.0%



Other countries represented:

Netherlands ● Finland ● Austria ● Portugal ● Israel
● Slovenia ● Ireland ● Canada ● Wales ● Jordan
● Greece ● Turkey ● Hungary ● Poland ● Czech Republic
● Brazil ● Scotland ● Malta ● China ● Japan ● Nigeria
● Norway ● South Korea ● Latvia

By investment priorities:

Stability	62.6%
Polymers	54.5%
Bioavailability	51.5%
Injection	50.5%
Oral delivery	46.5%
Excipients for injectables formulations	46.5%
Extended release	45.5%
Pre-formulation	44.4%
Solubility	41.4%
Excipients for solid dosage forms formulations	37.4%

Local Drug Delivery: Implants, Film, Fiber, Shapes, etc.	36.4%
Nanotechnology	36.4%
Innovative platforms	36.4%
Hot melt extrusion	34.3%
Dissolution	32.3%
Continuous manufacturing	32.3%
Laboratory equipment	31.2%
Excipients for semi-solids and liquids formulations	30.3%
Intellectual property	30.3%
Spray drying	28.3%



How to register

Delegate registration is open to companies with a drug development pipeline or proprietary drugs in the market and academic / non-profit / government institutions.

If you work for a **technology, service or solution provider** then you can only attend as a commercial partner. Please go to the next page for more information.

A delegate ticket includes:

- Access to all presentations on all 3 days
- Access to exhibition hall
- Potential for 2 pre-arranged 1-2-1 meetings with suppliers most likely to solve your challenges
- A light breakfast, full buffet lunch and refreshments on all 3 days
- 2 evening drinks receptions with canapes
- A discounted room rate at the venue hotel
- Access to all presentations made available by speakers after the summit
- Opportunity to submit a poster to the poster competition
- Access to the official summit app

Prices:

Early registration rates are still available.
Register soon to secure the best price.

Full Price: £1,495 + VAT

In order to maintain a comfortable and valuable networking experience, this year the summit will be limited to **500 attendees**. This means there are only **250 delegate places available** to purchase.

To register, please

Visit: www.ddfevent.com/delegate-registration

Email: maxconferences@markallengroup.com

Call: +44 (0) 207 738 5454



Become a Commercial Partner

As an official DDF Summit commercial partner, you can benefit from:

- **3 days of varied networking opportunities** - providing you with ample time to meet and get to know the 300+ pharma development leaders in attendance
- **Speaking positions within targeted, highly technical streams** - guaranteeing you a relevant and engaged audience
- **Exposure** in the pre- and post-summit marketing campaigns
- The chance for your team to get up to speed with the **latest innovations** and **advances** in drug delivery and formulation

There are a variety of options available to meet your business needs:

Business Development Package – a powerful injection of high quality leads into your pipeline

Thought Leadership Package – Intrigue, challenge and inspire with your innovative ideas and solutions

Bespoke Package – Tailored to suit your targets, goals and vision

Contact Alexandra for more information on the remaining opportunities.

Alexandra Krcho, Account Director
+44 (0) 203 874 9205 | alexandra.krcho@markallengroup.com



Venue

Maritim proArte Hotel Berlin

Friedrichstrasse 151
10117 Berlin
Germany

+49 30 20 335

Website

Accommodation

This is not included in your delegate ticket.
You will need to arrange your own accommodation.
However, we have arranged a discounted rate for all attendees at the Maritim proArte – more information is available [here](#)

Contact us

If you'd like to speak to us about anything at all then please use the details below:

General Enquiries:

+44 (0)20 7738 5454
maxconferences@markallengroup.com

Conference Content & Speaking:

Ahmed Osman, Programme Director
+ 44 (0)20 3874 9202
ahmed.osman@markallengroup.com

Sponsorship Enquiries:

Alexandra Krcho, Account Director
+ 44 (0) 203 874 9205
alexandra.krcho@markallengroup.com

Delegate Enquiries:

Adrian Forde, Delegate Sales Director
+ 44 (0)20 3874 9209
adrian.forde@markallengroup.com

Marketing & Media Enquiries:

Josh Lowth, Marketing Director
+44 (0)203 874 9210
josh.lowth@markallengroup.com



Follow us:

#DDFSummit

